Definitive Contract 75N91018C00048
Award Date
9/18/18
Potential Completion Date
9/17/20
Potential Value
$2M
Federal Agency
National Cancer Institute
Awardee
Radiomedix, Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Houston, TX 77042, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
2
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This contract was awarded by the National Cancer Institute, a civilian agency, to Radiomedix, Inc., a small disadvantaged business, for the Targeted Radionuclide Therapy of Neuroendocrine Tumors Using Pb212-Octreotate Analogs project. The contract has a ceiling value of $298,132.00 and was awarded under the Small Business Innovation Research (SBIR) Program Phase I. The contract is a Definitive Contract with a Firm Fixed Price pricing type and has an ultimate completion date of August 18, 2017.
This is a Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Radiopharmaceutical Imaging and Dosimetry, LLC, doing business as Radiopharmaceutical Imaging & Dosimetry LLC, a small business. The contract, valued at $299,275, is for a Small Business Innovation Research (SBIR) Phase I project to optimize targeted radionuclide therapy for metastatic liver cancer patients. This contract supports the NCI's broader...
<p>This is a Phase I Small Business Innovation Research (SBIR) contract awarded by the National Cancer Institute (NCI), a civilian agency, to Sibtech, Inc., a for-profit manufacturer, in the amount of $2,256,052.35. The contract is for the development of systemic radionuclide therapy targeted to VEGF receptors in tumor vasculature. The contract has a firm fixed price pricing type and an ultimate completion date of October 31, 2021. This contract is a set-aside for small businesses.</p>
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a Small Business Innovation Research (SBIR) Phase I contract to Radiopharmaceutical Imaging And Dosimetry, LLC (doing business as Radiopharmaceutical Imaging & Dosimetry LLC), a for-profit limited liability company. The $299,466.00 firm-fixed-price contract, which was set aside for small businesses, is for the development of user-friendly, platform-independent software to incorporate...
<p>This is a $298,934 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Houston Pharmaceutical Inc., a small business. The contract is for a Small Business Innovation Research (SBIR) Phase I project to develop a Targeted Radionuclide Therapy for Pancreatic Cancer. The contract has a period of performance through December 31, 2017. This award represents a set-aside for small businesses.</p>
<p>This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Imaginab, Inc. The contract, valued at $224,264, is for the development of novel imaging agents to expand the clinical toolkit for cancer diagnosis, staging, and treatment. The contract has a firm fixed-price pricing type and a completion date of September 29, 2012.</p>
This $2,399,183 firm-fixed-price SBIR Phase I contract was awarded by the National Cancer Institute (NCI) to Radiologics, Inc., a small business, to conduct research and development on cancer imaging tools and image de-identification software. The contract is part of the NCI's SBIR program, which aims to stimulate technological innovation and increase private sector commercialization of innovations derived from federal R&D. The contract has a period of performance through January 2024 and is...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institutes of Health (NIH) National Cancer Institute to Radiologics, Inc., a for-profit organization. The contract, valued at $225,000.00, is for the development of FDA-compliant imaging informatics for cancer research under SBIR Topic 365. As a SBIR Phase I award, this contract is set aside for small businesses. The contract has a firm fixed price pricing type and was awarded on September 18, 2017, with...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute, part of the National Institutes of Health at the Department of Health and Human Services. The $399,989 Firm Fixed Price contract was awarded to Molecular Targeting Technologies, Inc. (MTTI) on September 18, 2017 to develop a cancer-selective, phosphatidylserine (PS)-targeted radiolabeled nanovesicle system for targeted radionuclide therapy of brain tumors. The contract has a...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Oncotab, Inc. for the development of a targeted radionuclide therapy using tumor-specific antibodies for triple-negative breast cancer. The contract has a ceiling value of $300,000.00 and a performance period ending on January 31, 2018. As this is an SBIR Phase I contract, it represents an early-stage research and development effort for a novel cancer...